Abstract
In this review, the context and evidence base for intermittent and long term dosing with hypnotics is critically evaluated. The context provided includes addressing two questions: “why has long term or maintenance therapy not been a standard for practice for the treatment of chronic insomnia?”; and “why is intermittent dosing thought to represent a potential solution for the problem of chronic insomnia?”. The data from the systematic review suggests, over all, that: 1) while intermittent dosing can be conducted without resulting in rebound insomnia on non-med nights, there is insufficient data to show that the strategy is equal, or superior, to nightly dosing on a long term basis; 2) long term therapy (up to 6 months) with intermittent or nightly dosing appears viable to the extent that clinical outcomes are stable over time and occur in the absence of dose escalation or increased adverse events. The discussion section of the review includes: an analysis of the future prospects for intermittent dosing (with or without placebos); the suggestion that the use of placebos in an intermittent dosing regimen presages the use of partial reinforcement principles to enhance the safety and efficacy of the approach; finally the discussion contains a challenge to re-think, from first principles, whether the underlying approach to the medical management of insomnia is rational. It is suggested that a more rational approach is possible and that medical therapy for insomnia needs to be re-assessed for its curative (vs palliative) potential.
Keywords: Insomnia, pharmacotherapy, intermittent dosing, long term therapy
Current Pharmaceutical Design
Title: Intermittent and Long-Term Use of Sedative Hypnotics
Volume: 14 Issue: 32
Author(s): Michael Perlis, Philip Gehrman and Dieter Riemann
Affiliation:
Keywords: Insomnia, pharmacotherapy, intermittent dosing, long term therapy
Abstract: In this review, the context and evidence base for intermittent and long term dosing with hypnotics is critically evaluated. The context provided includes addressing two questions: “why has long term or maintenance therapy not been a standard for practice for the treatment of chronic insomnia?”; and “why is intermittent dosing thought to represent a potential solution for the problem of chronic insomnia?”. The data from the systematic review suggests, over all, that: 1) while intermittent dosing can be conducted without resulting in rebound insomnia on non-med nights, there is insufficient data to show that the strategy is equal, or superior, to nightly dosing on a long term basis; 2) long term therapy (up to 6 months) with intermittent or nightly dosing appears viable to the extent that clinical outcomes are stable over time and occur in the absence of dose escalation or increased adverse events. The discussion section of the review includes: an analysis of the future prospects for intermittent dosing (with or without placebos); the suggestion that the use of placebos in an intermittent dosing regimen presages the use of partial reinforcement principles to enhance the safety and efficacy of the approach; finally the discussion contains a challenge to re-think, from first principles, whether the underlying approach to the medical management of insomnia is rational. It is suggested that a more rational approach is possible and that medical therapy for insomnia needs to be re-assessed for its curative (vs palliative) potential.
Export Options
About this article
Cite this article as:
Perlis Michael, Gehrman Philip and Riemann Dieter, Intermittent and Long-Term Use of Sedative Hypnotics, Current Pharmaceutical Design 2008; 14 (32) . https://dx.doi.org/10.2174/138161208786549290
DOI https://dx.doi.org/10.2174/138161208786549290 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Augmentation Strategies for Clozapine-Resistant Patients with Schizophrenia
Current Pharmaceutical Design Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Review of Somnambulism in Children
Current Pediatric Reviews New Uses of Melatonin as a Drug; A Review
Current Medicinal Chemistry Two -Year Efficacy and Safety of Botulinum a Toxin Intravesical Injections in Patients Affected by Refractory Painful Bladder Syndrome
Current Drug Delivery Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Safety Profile of the Use of Second Generation Antipsychotics in the Child and Adolescent Population
Current Psychopharmacology Leishmaniasis: History, Evolution of Treatment and the Need for New Drugs
Current Biotechnology Intranasal Drug Delivery to the Central Nervous System: Present Status and Future Outlook
Current Pharmaceutical Design Medicinal Chemistry Approaches of Controlling Gastrointestinal Side Effects of Non-Steroidal Anti-Inflammatory Drugs. Endogenous Protective Mechanisms and Drug Design
Medicinal Chemistry Obstructive Sleep Apnea and Type 2 Diabetes: Dual Interaction
Current Respiratory Medicine Reviews Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry Investigation of <i>ACE rs4646994, MTHFR rs1801133</i> and <i>VDR rs2228570</i> Genotypes in Jordanian Patients with Fibromyalgia Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets On the Psychotropic Effects of Carbon Dioxide
Current Pharmaceutical Design Effect of Black Seed on Dextromethorphan O- and N-Demethylation in Human Liver Microsomes and Healthy Human Subjects
Drug Metabolism Letters Design, Synthesis and Pharmacological Evaluation of N3 Aryl/ Heteroaryl Substituted 2-((Benzyloxy and Phenylthio) Methyl) 6,7- dimethoxyquinazolin-4(3H)-ones as Potential Anticonvulsant Agents
Medicinal Chemistry Treating Obesity: Pharmacology of Energy Expenditure
Current Drug Targets Stimulant-Related Psychosis in ADHD Treatment: An Update for Past 10 Years
Current Psychopharmacology Bortezomib in Kidney Transplant: Current Use and Perspectives
Current Drug Metabolism